Open AccessSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study
Author(s) -
David Gordon,
Edward T. Hellriegel,
Heidi R. Hope,
David Burt,
Joseph B. Monahan
Publication year - 2021
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.685
H-Index - 27
ISSN - 1179-1438
DOI - 10.2147/cpaa.s305308
Subject(s) - tolerability , pharmacokinetics , medicine , pharmacodynamics , cmax , pharmacology , placebo , adverse effect , gastroenterology , pathology , alternative medicine
ATI-450 is an oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway. This phase 1, single and multiple ascending dose (SAD, MAD) study evaluated ATI-450 safety, tolerability, pharmacokinetics, and pharmacodynamics.